Accueil
PDX List from gustave roussy. For more information contact Ludovic Bigot
PDX IdCohortHistologyDisease StatusTreatmentPrior treatmentMolecular DriverPhenotypeClinical HistoryMolecular CharacterizationParaffin BlockPharmaco Validation
ST-9917_PDX1 KRAS pancreas baseline XXX KRAS:p.(Gly12Cys) No No Yes No
ST-9797_PDX1 nectine-4 bladder baseline XXX No No No No
ST-7292_PDX1 KRAS colon progression disease XXX KRAS:p.(Gly12Cys) Yes No Yes No
ST-9624_PDX1 ALK lung baseline XXX No No No No
ST-9370_PDX1 KRAS lung baseline XXX KRAS:p.(Gly12Asp) No No No No
ST-9406_PDX1 KRAS pancreas baseline XXX FOLFIRINOX; Gemcitabine - Paclitaxel KRAS:p.(Gly12Asp) adenocarcinoma Yes No Yes No
ST-9406_PDX2 KRAS pancreas suivie XXX Folforinox; Gemcitabine - Paclitaxel KRAS:p.(Gly12Asp) Yes No No No
ST-9307_PDX1 ALK lung baseline (no treatment) XXX Lorlatinib EML4::ALK fusion Yes No No No
ST-9217_PDX1 TP53 gynecological ovary baseline XXX TP53 Y220C high-grade serous ovarian adenocarcinoma Yes No No No
ST-9022_PDX1 other gynecological uterus progression disease reclassify as a gynecological (uterine) tumor Cisplatin; Carboplatin-taxol-avastin-pembrolizumab KRAS - p.(Gly12Ser) epidermoid carcinoma Yes No No No
ST-9020_PDX1 FGFR cutaneous basosquamous carcinoma baseline XXX FGFR3:p.(Lys650Met) basosquamous carcinoma No No No No
ST-9020_PDX2 FGFR cutaneous basosquamous carcinoma progression disease XXX FGFR3:p.(Lys650Met) basosquamous carcinoma No No No No
ST-2563_PDX1 KRAS colon progression disease XXX FOLFOX; TOMOX; TOMIRI; LONGSURF - bevacizumab; LONGSURF - Avatin; Regorafenib KRAS:p.(Gly12Asp) Adenocarcinoma Yes No Yes No
ST-8660_PDX1 ALK lung baseline XXX ALK G1202R No No No No
ST-2864_PDX1 nectine-4 bladder baseline XXX No No No No
ST-8500_PDX1 KRAS lung baseline Sotorasib Alimta-Carboplatin-Pembrolizumab KRAS:p.(Gly12Cys) Yes No Yes No
ST-8534_PDX1 KRAS lung baseline Sotorasib Carboplatin-pemetrexed-pembrolizumab KRAS - p.(Gly12Val) Yes No Yes No
ST-7936_PDX1 EGFR lung progression disease Osimertinib Yes No Yes No
ST-4062_PDX1 prostate prostate baseline XXX Abiratenone - hormonotherapie - docetaxel AR amplification, TMPRSS2--ERG fusion Yes No Yes No
ST-7880_PDX1 nectine-4 bladder baseline (primary resistance) XXX BCG; Cisplatin-gemcitabine; pembrolizumab; XXX FGFR3:p.(Ser249Cys) Yes No Yes Yes
ST-3027_PDX1 prostate prostate baseline XXX Decapeptyl; Enzalutamide -/-Talazoparib; Abiraterone-prednisone-atorvastatine; Abiraterone-dexamethasone-atorvastatine; ODM208; Docetaxel AR T878A, V716M Yes No Yes No
ST-7019_PDX1 KRAS lung baseline Sotorasib KRAS:p.(Gly12Cys) Yes No Yes Yes
ST-7614_PDX1 KRAS lung baseline Sotorasib Cisplatin-navelbine; Carboplatin-pembrolizumab-alimta KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes No Yes No
ST-6867_PDX1 FGFR squamous cell carcinoma of the penis baseline XXX TIP; TIP-5FU-mitomycine; Nivolumab FGFR3:p.(Ser249Cys) Yes No Yes No
ST-7413_PDX1 prostate prostate baseline XXX Apalutamide; Abiraterone - prednisone; Docetaxel; Cabazitaxel; Carboplatin etoposide; mitoxantrone AR amplification, TMPRSS2 TMPRSS2-ERG fusion squamous cell carcinoma Yes No Yes No
ST-7520_PDX1 nectine-4 bladder progression disease XXX Carboplatin; Navelbine; Pembrolizumab FGFR3::TACC3 fusion Yes No Yes Yes
ST-7442_PDX1 nectine-4 bladder baseline XXX MVAC; Cisplatin-capecitabine; Pembrolizumab TP53 p. E258K Yes No Yes No
ST-5176_PDX1 prostate prostate progression disease XXX Abiraterone - zoladex; Firmagon; docetaxel; enzalutamide puis denosumab puis zoladex; Cabazitaxel; Paclitaxel; Navelbine Carboplatin AR amplification Yes No Yes No
ST-6535_PDX1 prostate prostate baseline XXX Enantone; Apalutamide-dectancyl-bicalutamide; Docetaxel; Cabazitaxel; Novantrone AR:p.(Val716Met) Yes No Yes No
ST-6806_PDX1 nectine-4 bladder baseline XXX MVAC; Avelumab PIK3CA E545K Yes No Yes No
ST-6185_PDX1 EGFR lung under treatment Osimertinib No No Yes No
ST-0849_PDX1 prostate prostate progression disease XXX hormono therapy - docetaxel; Denosumab; Enzalutamide; Ra223; Abiraterone PTEN deletion, RB1 deletion mixed phenotype Yes No Yes No
ST-4085_PDX1 EGFR lung progression disease Lazertinib-amivantamab Osimertinib EGFR deletion exon 19 squamous cell carcinoma (épidermoid) Yes No Yes No
ST-6742_PDX1 nectine-4 bladder baseline XXX Carboplatin-gemza; Pembrozilumab Luminal Papillary Yes No Yes Yes
ST-7018_PDX1 nectine-4 bladder progression disease XXX BCG-thérapie; Cisplatin-gemzar; Avelumab TP53:p.(Gln192Ter) Luminal Unstable Yes Yes Yes No
ST-6372_PDX1 KRAS lung baseline Sotorasib Carboplatin-paclitaxel-pembrolizumab KRAS:p.(Gly12Cys) squamous cell carcinoma (épidermoide) Yes Yes Yes Yes
ST-6263_PDX1 nectine-4 bladder baseline Pembrolizumab Cisplatin-gemcitabiine; Pembrolizumab PIK3CA:p.(Glu545Lys) Basal Squamous Yes Yes Yes Yes
ST-6263_PDX2 nectine-4 bladder baseline XXX Cisplatin-gemcitabine; Pembrozilumab PIK3CA:p.(Glu545Lys) Basal Squamous Yes Yes Yes Yes
ST-6714_PDX1 KRAS lung baseline Sotorasib Cisplatin-vinorelbine; Cisplatin-pémétrexed-pembrolizumab; Dostarlimab-docetaxel; Docetaxel KRAS:p.(Gly12Cys) papillary adenocarcinoma Yes Yes Yes No
RET-IGR-01_PDX1 RET lung progression disease Selpercatinib Pemetrexed-Carboplatin KIF5::RET fusion NSCLC adenocarcinoma Yes Yes Yes No
ST-6598_PDX1 EGFR lung baseline Osimertinib EGFR deletion exon 19 sarcomatoide carcinoma Yes No Yes No
ST-5526_PDX1 nectine-4 bladder progression disease XXX Cisplatin-gemzar; Carboplatin; Pembrolizumab TP53:p.(Arg175His) Basal Squamous Yes No Yes No
ST-6566_PDX1 EGFR lung progression disease Osimertinib EGFR:p.(Leu858Arg) NSCLC adenocarcinoma Yes Yes Yes Yes
ST-5979_PDX1 KRAS cholangiocarcinoma progression disease XXX Xeloda; Cisplatin-durvalumab-gemcitabine KRAS:p.(Gly12Cys) Yes Yes Yes No
ST-3075_PDX1 ROS1 lung progression disease XXX Femara; Aromasine; Anastrozole; Crizotinib SDC4::ROS1 Fusion NSCLC adenocarcinoma Yes Yes Yes Yes
ST-0293_PDX1 KRAS colon progression disease XXX FOLFIRI-bevacizumab-5FU; Capécitabine-bevacizumab; LV5FU2-bevacizumab KRAS:p.(Gly12Cys) Yes Yes Yes No
ST-6201_PDX1 KRAS lung baseline Sotorasib Carboplatin-pemetrexed-pembrolizumab KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
ST-6105_PDX1 KRAS lung baseline Sotorasib Cisplatin-pémétrexed-pembrolizumab KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
ST-4352_PDX1 EGFR lung progression disease Osimertinib EGFR deletion exon 19 NSCLC adenocarcinoma Yes Yes Yes No
ST-5923_PDX1 EGFR lung progression disease Osimertinib EGFR deletion exon 19 NSCLC adenocarcinoma Yes No Yes No
ST-5016_PDX1 KRAS lung baseline Sotorasib Cisplatin-vinorelbine-Rx; Durvalumab; Pembrolizumab KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
ST-4036_PDX1 FGFR cholangiocarcinoma progression disease XXX Gemcitabine-Cisplatin; FOLFOX FGFR2::WAC fusion Yes No Yes No
ST-5472_PDX1 EGFR lung baseline Osimertinib Docetaxel EGFR:p.(Leu858Arg), EGFR:p.(Leu833Val) NSCLC adenocarcinoma Yes No Yes No
ST-5242_PDX1 FGFR bladder baseline XXX MVAC; Pembrolizumab; Paclitaxel; Erdafitinib FGFR3:p.(Tyr373Cys) Luminal Papillary Yes Yes Yes No
ST-5469_PDX1 ALK lung baseline XXX Alectinib; Lorlatinib; Cisplatin-pemetrexed EML4::ALK fusion NSCLC adenocarcinoma Yes No Yes No
ST-5010_PDX1 ALK lung baseline (primary resistance) XXX CDDP-ALIMTA; Crizotinib; Lorlatinib; Carboplatin-pemetrexed-bevacizumab EML4::ALK fusion NSCLC adenocarcinoma Yes Yes Yes No
ST-5010_PDX2 ALK lung progression disease XXX CDDP-ALIMTA; Crizotinib; Lorlatinib; Carboplatin-pemetrexed-bevacizumab EML4::ALK fusion NSCLC adenocarcinoma Yes Yes Yes No
ST-4193_PDX1 FGFR cholangiocarcinoma progression disease XXX GEMOX FGFR2:p.(Cys382Arg) Yes Yes Yes Yes
ST-4764_PDX1 KRAS lung baseline XXX Carboplatin-pemetrexed-pembrolizumab; Carboplatin-pemetrexed; Docetaxel; Gemcitabine; Paclitaxel; SGNB6A-001 KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
ST-3227_PDX1 FGFR pancreas progression disease XXX FOLFIRINOX; FOLFIRI; LV5FU2; Carboplatin-gemcitabine FGFR2::INA fusion Yes Yes Yes Yes
ST-5013_PDX1 EGFR lung progression disease Osimertinib EGFR:p.(Leu858Arg) NSCLC adenocarcinoma Yes No Yes No
ST-2405_PDX1 FGFR cholangiocarcinoma progression disease XXX GEMZAR-CDDP; FOLFOX FGFR2:p.(Leu776fs*6) Yes Yes Yes No
ST-2543_PDX1 FGFR cholangiocarcinoma progression disease XXX GEMZAR-CDDP; FOLFOX FGFR2::KIAA1217 fusion Yes Yes Yes No
ST-4772_PDX1 nectine-4 bladder baseline XXX Avelumab; Carboplatin-gemcitabine; Pembrolizumab FGFR3:p.(Arg249Cys) Basal Squamous Yes Yes Yes Yes
ST-4451_PDX1 KRAS lung baseline XXX Carboplatin-taxol-pembrolizumab; Pembrolizumab; Sotorasib KRAS:p.(Gly12Cys) NSCLC adenocarcinoma Yes No Yes No
ST-0899_PDX1 ALK lung progression disease Brigatinib Alectinib EML4::ALK fusion Yes Yes Yes No
ST-3498_PDX1 ALK lung progression disease Alectinib (primary resistance) EML4::ALK fusion NSCLC adenocarcinoma Yes Yes Yes No
ST-2726_PDX2 FGFR cholangiocarcinoma baseline XXX Cisplatin-gemcitabine; XXX; FOLFOX; FOLFIRI; Taxol FGFR2::PLEKHA4 fusion Yes Yes Yes No
MR556_PDX2 EGFR lung progression disease Osimertinib EGFR:p.(Gly719Ala), EGFR:p.(Glu709Ala) NSCLC adenocarcinoma Yes Yes Yes No
M2267_PDX1 other nut middeline progression disease OTX015 NUTM1 réarangement Yes No Yes No
ST-4029_PDX1 thyroid anaplasic head and neck (thyroid) baseline Carboplatin-paclitaxel AFAP1L2-BRAF fusion, TP53:p.(Cys176Ter) thyroid anaplasic Yes Yes Yes No
ST2577_PDX1 RET head and neck (thyroid) progression disease Selpercatinib iode 131; Lenvatanib NCOA4::RET fusion Yes Yes Yes No
ST2099_PDX1 KRAS pleural progression disease Sotorasib Cisplatin-navelbine; Carboplatin-alimta-pembrolizumab KRAS:p.(Gly12Cys) Yes Yes Yes No
ST3511_PDX1 ROS1 lung baseline (primary resistance) XXX Cisplatin-alimta,; Crizotinib; Lorlatinib; Carboplatin-alimta-avastin CD74::ROS1 fusion, TP53:p.(Arg213Ter) NSCLC adenocarcinoma Yes Yes Yes No
MR1220_PDX1 EGFR lung progression disease Osimertinib EGFR:p.(Leu858Arg), PIK3CA:p.(Glu545Lys),FGFR3::TACC3 fusion NSCLC adenocarcinoma Yes Yes Yes No
ST-3973_PDX2 ALK lung progression disease Lorlatinib Crizotinib EML4::ALK fusion NSCLC adenocarcinoma Yes Yes Yes No
MR-1284_PDX1 KRAS pancreas baseline Brigatinib Ceritinib KRAS:p.(Gly12Asp) Yes Yes Yes No
MR-1253_PDX1 EGFR lung baseline (sensitive) ADC TROP2 Osimertinib; Cisplatin-pemetrexed-pembrolizumab; Gemcitabine EGFR deletion ex 19, EGFR amplification, TP53 p.(Ile195Thr) NSCLC adenocarcinoma Yes Yes Yes No
MR-1271_PDX1 FGFR duodenum progression disease Futibatinib FOLFOX; FOLFIRI FGFR2-NEK1 fusion, TP53:p.(Tyr236SerfsTer11), APC:p.(Glu1397Ter) Yes Yes Yes No
MR-1259_PDX1 KRAS pancreas baseline XXX FOLFIRINOX; Gemcitabine; Taxol KRAS:p.(Gly12Asp), TP53:p.(Gly245Ser), SMARCA4 A4 splice site 1813-2A>T, PIK3CA:p.(Glu545Lys) Yes Yes Yes No
MR-1197_PDX1 DDR gynecological ovary progression disease Niraparib Carboplatin-avastin CDK12:p.(Leu636PhefsTer4), KRAS amplification, TP53:p.(Cys238Tyr) Yes Yes Yes No
MR1154-R_PDX1 FGFR pancreas progression disease XXX Futibatinib; FOLFOX; FOLFIRI; Gemcitabine FGFR2-CCSER2 fusion, RBM5:p.(Arg690Ter) Yes Yes Yes No
MR1257_PDX1 KRAS pancreas baseline Gemzar-abraxane FOLFIRINOX KRAS:p.(Gly12Asp), PIK3CA:p.(His1047Arg), TP53:p.(Arg337Cys) Yes Yes Yes No
MR1249_PDX1 KRAS pancreas baseline XXX FOLFIRINOX; Gemcitabine; FOLFOX; Taxol KRAS:p.(Gly12Asp), TP53:p(.Cys141Gly), HIRA:(p.Lys27Ter), CCNE1 amplification Yes Yes Yes No
MR1247_PDX1 KRAS pancreas baseline XXX FOLFIRINOX KRAS:p.(Gly12Asp) Yes Yes Yes No
MR1031_PDX1 KRAS lung progression disease Sotorasib Cisplatin-pemetrexed; Carboplatin-paclitaxel-pembrolizumab KRAS p.Gly12Cys, PIK3CA:p.(Glu545Lys), STK11:p.(Glu293Ter), SMARCA4:p.(Thr938IlefsTer7) - p.(Thr938_Phe939insSerSer) NSCLC adenocarcinoma Yes Yes Yes Yes
MR1025_PDX1 DDR prostate progression disease Rucaparib Enzalutamide; Docetaxel BRCA2:p.(Cys2689LeufsTer4), AR amplification, TP53:p.(His178ThrfsTer69), RAD21 amplification Yes Yes Yes Yes
MR1016_PDX1 HER2 lung baseline TDXT Carboplatin-pemetrexed-pembrolizumab ERBB2:p.(Ala775_G776insTyrValMetAla), SMARCD1:p.(Glu356Ter), BRAF -- SAMD9 fusion NSCLC adenocarcinoma Yes Yes Yes Yes
MR1010_PDX1 EGFR lung progression disease Osimertinib first EGFR:p.(Leu858Arg), MET amplification, TP53:p.(Arg282Trp) acinar adenocarcinoma Yes Yes Yes No
MR1238_PDX1 HER2 lung progression disease Trastuzumab deruxtecan RX-Durvalumab; Carboplatin-taxol-pembrolizumab; Navelbine ERBB2:p.(Ser310Phe), KRAS:p.(Gly12Asp) squamous cell carcinoma (épidermoid) Yes Yes Yes No
MR1188_PDX1 ALK lung progression disease Alectinib EML4::ALK fusion, ALK:p.(Val1180Leu) NSCLC adenocarcinoma Yes Yes Yes No
MR1168_PDX1 NTRK Lung neuroendocrine progression disease Repotrectinib Etoposide-Carboplatin-immunotherapie; Repotrectinib; Etoposide-Carboplatin-larotrectinib EML4::NTRK3 fusion, NTRK:p.(Gly623Arg) Yes Yes Yes No
MR1156_PDX1 EGFR lung progression disease Osimertinib EGFR:p.(Leu858Arg), TP53 p.(Tyr327LeufsTer10) NSCLC adenocarcinoma Yes Yes Yes No
MR1148_PDX1 FGFR cholangiocarcinoma baseline XXX FOLFOX; FOLFIRI; Cisplatin-gemcitabine BICC1-FGFR2, BAP1 (p.K580Rfs*37), NF2 p.Glu541Ter, PIK3CA p.E545K Yes Yes Yes No
MR1130_PDX1 KRAS colon baseline (primary resistance) XXX FOLFOX-bevacizumab; LV5FU2-bevacizumab; FOLFIRI-bevacizumab; LONSURF-bevacizumab KRAS:p.(Gly12Cys), TP53:p.(Pro250Leu) Yes Yes Yes Yes
MR1055_PDX1 NTRK lung baseline Entrectinib Carboplatin-ectoposide-atezolizumab; Carboplatin-taxol-avastin EML4::NTRK2 fusion, ATM:p.(Phe1036fs*11), EGFR:p.(Leu858Arg) Yes Yes Yes No
MR1030_PDX1 thyroid anaplasic head and neck (thyroid) progression disease Clever1 inhibiteur Rx-Carboplatin-taxol TP53:p.(Lys164Ter), STK11 Deletion, PTEN:p.(His93Pro) thyroid anaplasic Yes Yes Yes No
MR1029_PDX1 KRAS lung baseline Sotorasib Alimta-platine-pembrolizumab KRAS:p.(Gly12Cys), STK11:p.(His174Pro), SMARCA4:p.(Thr1156SerfsTer3) NSCLC adenocarcinoma Yes Yes Yes Yes
MR1029_PDX2 KRAS lung baseline Sotorasib Alimta-platine-pembrolizumab KRAS:p.(Gly12Cys), STK11:p.(His174Pro), SMARCA4:p.(Thr1156SerfsTer3) NSCLC adenocarcinoma Yes Yes Yes Yes
MR1029_PDX3 KRAS lung under treatment Sotorasib Alimta-platine-pembrolizumab KRAS:p.(Gly12Cys), STK11:p.(His174Pro), SMARCA4:p.(Thr1156SerfsTer3) NSCLC adenocarcinoma Yes Yes Yes Yes
MR1108_PDX1 BRAF head and neck (thyroid) baseline Dabrafenib-trametinib BRAF:p.(Val600Glu), NF2:p.(Ser288Ter), MDM2 amplification, AKT1:p.(Glu17Lys) Yes Yes Yes No
MR902_PDX1 thyroid anaplasic head and neck (thyroid) progression disease Clever1 inhibiteur Cisplatin-adriamycine-Rx PTEN:p(Glu256fs*42), RB1:p.(Arg358Ter), TP53:p.(Phe134fs*38) Yes Yes Yes No
MR892_PDX1 EGFR lung progression disease Osimertinib Erlotinib EGFR deletion ex 19, EGFR amplification, TP53:p.(Gln331Ter) NSCLC adenocarcinoma Yes Yes Yes No
MR886_PDX1 EGFR lung progression disease Osimertinib Gefitinib EGFR:p.(Leu858Arg), ROS1:(p.Arg2039Cys) NSCLC adenocarcinoma Yes Yes Yes No
MR876_PDX1 EGFR lung progression disease Osimertinib EGFR deletion exon 19, SETD2 p.(Gln2362Ter), ERBB3 p.(Asn953Ser), TP53:p.(Glu336Ter) papillary adenocarcinoma Yes Yes Yes No
MR869_PDX1 KRAS lung progression disease Sotorasib Cisplatin-pemetrexed-pembrolizumab; Paclitaxel-bevacizumab KRAS:p.(Gly12Cys), STK11 splice site 465-1_465GG>TT, CDK4 amplification, MDM2 amplification NSCLC adenocarcinoma Yes Yes Yes Yes
MR847_PDX1 FGFR cholangiocarcinoma baseline pemigatinib FOLFOX; Gemcitabine-cipslatine FGFR2::PHC1 fusion Yes Yes Yes No
MR835_PDX1 KRAS pancreas baseline (primary resistance) IPH5201 -/- durvalumab -/- oleclumab FOLFIRINOX; FOLFIRI; Eryaspase-gemcitabine-abraxane KRAS:p.(Gly12Asp) Yes Yes Yes No
MR835_PDX2 KRAS pancreas baseline (primary resistance) IPH5201 -/- durvalumab -/- oleclumab FOLFIRINOX; FOLFIRI; Eryaspase-gemcitabine-abraxane KRAS:p.(Gly12Asp) Yes Yes Yes No
MR820_PDX1 EGFR lung baseline Osimertinib Gefitinib EGFR deletion exon 19, NRTK1 et RET fusion besoin validation RNAseq, ERBB3:p.(Ala116Val) NSCLC adenocarcinoma Yes Yes Yes Yes
MR803_PDX1 thyroid anaplasic head and neck (thyroid) baseline (sensitive) Dabrafenib-trametinib Rx - Cisplatin-adriamycine TP53:p.(Cys124LeufsTer25), NF1 splice site 3197-2T>G , BRAF:p(.Lys499Asn) Yes Yes Yes No
MR761_PDX1 KRAS lung baseline Sotorasib Cisplatin-pemetrexed-pembrolizumab KRAS:p.(Gly12Cys), MET::SMYD3 fusion NSCLC adenocarcinoma Yes Yes Yes Yes
MR759_PDX1 KRAS gynecological ovary progression disease Trametinib Carboplatin-docetaxel; Carboplatin--aelyx-avastin; Carboplatin-bevacuzimab-/-atezolizumab; Caelyx KRAS:p.(Gly12Asp), KRAS amplification serous papillary ovarian carcinoma Yes Yes Yes No
MR748_PDX1 prostate prostate baseline Enzalutamide NCOR2:p.(Gln667Alafs*37), PTEN deletion, TP53:p.(Ser149Profs*21), XXX luminal phenotype Yes Yes Yes No
MR723_PDX1 DDR gynecological ovary progression disease Olaparib Carboplatin-taxol; Carboplatin-gemcitabine BRCA2:p.(Tyr1894Ter), BRCA2:p.(Tyr1894Lys), MTOR:p.(Glu2419Lys), PARP2:p.(Ala87Gly), MED12::IRF2BPL fusion serous papillary carcinoma Yes Yes Yes No
MR719_PDX1 FGFR cholangiocarcinoma baseline Futibatinib FOLFOX; Cisplatin-gemzar FGFR2::SORBS2 fusion, FGFR2:p.(Ser110ValfsTer4), FGFR2:p.(Arg111Ter) Yes Yes Yes No
MR701_PDX1 FGFR cholangiocarcinoma baseline Futibatinib FOLFOX; Gemcitabine-cipslatine SNHG27::FGFR2 fusion, EGFR deletion ex 19, TP53:p.(Met237Ile), SF3B1:p.(Lys700Glu) Yes Yes Yes No
MR696_PDX1 DDR gynecological ovary progression disease Niraparib Carboplatin-avastin RAD51C:p.(Ile244MetfsTer9), CCNE1 amplification, TP53:p.(Arg248Trp) Yes Yes Yes No
MR646_PDX1 FGFR cholangiocarcinoma progression disease Futibatinib Cisplatin-gemzar; FOLFOX FGFR2::TACC2 fusion, BAP1:p.(Lys425SerfsTer5), LPP:p.(Ser227Ter) Yes Yes Yes No
MR622_PDX1 other nut middeline progression disease BI1367 (inhibiteur de BET) BRD4::NUTM1 fusion, AKT1 p.(Glu17Lys), TP53 p.(Gly245Asp) Yes Yes Yes Yes
MR619_PDX1 ALK cholangiocarcinoma progression disease Alectinib Gemzar-Cisplatin-Pembrolizumab; Nab-Paclitaxel-Gemcitabin STRN::ALK fusion, ALK:p.(Gly1202Arg), TP53:p.(Arg282Trp) Yes Yes Yes Yes
MR602_PDX1 FGFR cholangiocarcinoma progression disease Futibatinib FOLFOX; FOLFIRI; Gemcitabine-cisplatin; Docetaxel FGFR2::MITF fusion, FGFR3:(p.Val754Met), JAK3:p.(Asp123Asn), ATM:p.(Ile1804_Trp1805insTer) Yes Yes Yes No
MR600_PDX1 ALK lung progression disease Alectinib EML4::ALK fusion, NF1 p.(Lys1385Arg) NSCLC adenocarcinoma Yes Yes Yes No
MR600_PDX2 ALK lung progression disease Alectinib EML4::ALK fusion, multiple amplification (MET, EGFR, BRAF) NSCLC adenocarcinoma Yes Yes Yes Yes
MR590_PDX1 EGFR lung progression disease Osimertinib Gefitinib; Cisplatin EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Cys797Ser) NSCLC adenocarcinoma Yes Yes Yes No
MR587_PDX1 EGFR lung progression disease Osimertinib Cisplatin; Gefitinib EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Cys797Ser), EGFR amplification, NRG1--RBPMS fusion NSCLC adenocarcinoma Yes Yes Yes Yes
MR577_PDX1 ALK lung progression disease Lorlatinib EML4::ALK fusion, PIK3C2B:p.(Thr474IlefsTer10) NSCLC adenocarcinoma Yes Yes Yes No
MR563_PDX1 BRAF head and neck (thyroid) progression disease Dabrafenib-trametinib BRAF:p.(Val600Glu), TP53:p.(Tyr163Cys) Yes Yes Yes No
MR527_PDX1 ALK lung progression disease Lorlatinib Alectinib EML4-ALK fusion, KRAS amplification, MDM2 amplification, CDK4 amplification Yes Yes Yes No
MR513_PDX1 KRAS pancreas progression disease Sotorasib FOLFIRINOX; FOLFIRI; Gemzar-abraxane-FOLFOX KRAS:p.(Gly12Cys), SMAD4 deletion, TP53:.(Arg280Lys) Yes Yes Yes Yes
MR503_PDX1 EGFR lung progression disease Osimertinib Gefitinib EGFR deletion exon 19, EGFR amplification, TP53:p.(His193Arg), CDKN2A p.(Pro94Leu); p.(Arg80Ter) NSCLC adenocarcinoma Yes Yes Yes No
MR491_PDX1 EGFR lung progression disease Osimertinib first EGFR deletion exon 19, PARD3::RET fusion, PIK3CA:p.(Arg108His), TP53:p.(Gly334Val) NSCLC adenocarcinoma Yes Yes Yes No
MR480_PDX1 ALK lung progression disease Lorlatinib Crizotinib; Cisplatin CD74::ROS1 fusion, TP53:p.(Ala276Pro) NSCLC adenocarcinoma Yes Yes Yes No
MR478_PDX1 EGFR lung progression disease Osimertinib first EGFR deletion exon 19, PIK3CA:p.(Glu545Lys), KRAS:p.(Gly12Arg) NSCLC adenocarcinoma Yes Yes Yes Yes
MR468_PDX1 ALK lung progression disease Alectinib 1st line (lorla resistant) Lorlatinib EML4::ALK fusion, PIK3CA:p.(Glu545Lys), PTEN splice Ex5 NSCLC adenocarcinoma Yes Yes Yes Yes
MR448_PDX1 ALK lung progression disease Lorlatinib Crizotinib; Alectinib; Brigatinib EML4::ALK fusion, ALK:p.(Thr1151Met), ALK:p.(Gly1202Arg), MDM2 amplification Yes Yes Yes Yes
MR445_PDX1 EGFR lung progression disease Erlotinib Carboplatin EGFR deletion exon 19, amplification KRAS, SMAD4:p.(Arg361Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
MR441_PDX1 EGFR lung progression disease Osimertinib Gefitinib EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Cys797Gly), EGFR amplification NSCLC adenocarcinoma Yes Yes Yes Yes
MR436_PDX1 EGFR lung progression disease Erlotinib EGFR:p.(Leu858Arg), ERBB2 amplification, TP53:p.(Arg175His) NSCLC adenocarcinoma Yes Yes Yes Yes
MR432_PDX1 other lymphoma B progression disease CMAK683X2101 EED inhibiteur CHOP; DHAP; GEMOX; ICE; Nivolumab ; anti CD37; CC122 ; GA101 ; Tazemetostat; r-caelyx-endoxan-methotrexate; CMAK683X2101 (inhibiteur de EED)  TP53 p.Arg175His Yes Yes Yes No
MR415_PDX1 BRAF appendiceal adenocarcinoma progression disease Vemurafenib Cetuximab; FOLFOX; FOLFIRI; LV5FU2 BRAF:p.(Val600Glu), AKT1:(p.Glu17Lys), APC:p.(Gln1549Ter) - p.(Tyr1162Ter), NOTCH1 amplification, NRTK1 amplification Yes Yes Yes No
MR411_PDX1 FGFR bladder progression disease pemigatinib Carboplatin/gemzar/pembrolizumab FGFR3:p.(Tyr373Cys), TUBB2B:(p.Ala9Val) High-grade papillary carcinoma Yes Yes Yes No
MR406_PDX1 FGFR bladder progression disease pemigatinib Carboplatin/gemzar/pembrolizumab FGFR3:p.(Ser249Cys), amplification FGFR1 , EGFR deletion ex 19, ATM:p.(Gln1982ArgfsTer8) Luminal Papillary Yes Yes Yes No
MR393_PDX1 EGFR lung progression disease Osimertinib first EGFR:p.(Leu858Arg), FGFR3::TACC3 fusion, MDM2 amplification Yes Yes Yes Yes
MR387_PDX1 EGFR lung progression disease Erlotinib EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Val769Met), TP53:p.(Ser241Cys) NSCLC adenocarcinoma Yes Yes Yes Yes
MR369_PDX1 FGFR cholangiocarcinoma progression disease pemigatinib Gemcitabine-oxaliplatine FGFR2::INA fusion, FGFR2:p.(Val564Leu), ERBB3:p.(Ser717Leu) Yes Yes Yes Yes
MR347_PDX1 ALK lung progression disease Ceritinib Cisplatin-pemetrexed; Crizotinib EML4::ALK fusion, TP53:p.(Arg273His), XXX NSCLC adenocarcinoma Yes Yes Yes Yes
MR344_PDX1 ALK lung progression disease Ceritinib Crizotinib EML4::ALK fusion, ALK:p.(Phe1174Leu) NSCLC adenocarcinoma Yes Yes Yes Yes
MR341_PDX1 KRAS lung baseline Sotorasib Cisplatin - navelbine; Nivolumab; Carboplatin-Alimta-Bévacizumab; Taxol-avastin KRAS:p.(Gly12C, KRAS amplification, TP53:p.Glu294Ter NSCLC adenocarcinoma Yes Yes Yes Yes
MR332_PDX1 FGFR cholangiocarcinoma progression disease Erdafitinib Docetaxel; Carboplatin; FOLFIRI FGFR::BICC1 fusion, FGFR2:p.(Val564Phe), ROS1:p.(Gly1757Ser) Yes Yes Yes Yes
MR322_PDX1 EGFR lung progression disease Osimertinib EGFR deletion exon 19, NRAS:p.(Gln61Leu), TP53 p.Lys320Ter NSCLC adenocarcinoma Yes Yes Yes No
MR320_PDX1 BRAF lung progression disease Dabrafenib Cisplatin-vinorelbine BRAF V600E, TP53 p.Gln192* NSCLC adenocarcinoma Yes Yes Yes Yes
MR313_PDX1 FGFR cholangiocarcinoma progression disease pemigatinib FOLFIRINOX; FOLFIRI FGFR2::STRN4 fusion, FGFR2:p.(Asp650His) Yes Yes Yes Yes
MR283_PDX1 prostate prostate progression disease Enzalutamide Hormono therapy AR amplification, TP53 truncating, ARID2 truncating mixed phenotype Yes Yes Yes No
MR260_PDX1 EGFR lung progression disease Osimertinib Afatinib; Gefitinib EGFR deletion exon 19, MDM2 amplification, MTOR:p.(Ala1713SerfsTer38) NSCLC adenocarcinoma Yes Yes Yes No
MR248_PDX1 FGFR bladder progression disease Erdafitinib Atezolizumab FGFR3:p.(Tyr373Cys), MSH6 cause hypermutated, TP53:p.(Gly245Ser), ERBB3:p.(Val104Met), KRAS:p.(Ala146Thr) Luminal Papillary Yes Yes Yes Yes
MR371_PDX2 FGFR bladder progression disease Futibatinib Atezolizumab; Erdafitinib FGFR3:Y373C , PIK3CA R88Q , MSH6 cause hypermutated Luminal Papillary Yes Yes Yes No
MR246_PDX1 FGFR bladder progression disease Erdafitinib Gemcitabine-oxaliplatine; Carboplatin FGFR3:p.(Ser249Cys), KMT2D:p.(Gln1402Ter) Luminal Papillary Yes Yes Yes No
MR242_PDX1 EGFR lung progression disease Osimertinib Cisplatin; Gefitinib; Erlotinib; Carboplatin; Afatinib EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Cys797Ser), EGFR::PTPN9 fusion NSCLC adenocarcinoma Yes Yes Yes Yes
MR240_PDX1 EGFR lung progression disease Osimertinib Erlotinib EGFR deletion exon 19, EGFR:p.(Thr790Met), STRN::ALK fusion, TP53:p.(Lys132ValfsTer15) NSCLC adenocarcinoma Yes Yes Yes Yes
MR240_PDX2 EGFR lung progression disease Brigatinib Erlotinib; Osimertinib EGFR deletion exon 19, EGFR:p.(Thr790Met), STRN::ALK fusion, EGFR amplification, TP53:p.(Lys132ValfsTer15) NSCLC adenocarcinoma Yes Yes Yes No
MR228_PDX1 EGFR lung progression disease Osimertinib Gefitinib; Afatinib EGFR deletion exon 19, TP53:p.(Val147SerfsTer13) NSCLC adenocarcinoma Yes Yes Yes Yes
MR221_PDX1 EGFR lung progression disease Osimertinib Gefitinib EGFR deletion exon 19, TP53:p.(Val157Phe) NSCLC adenocarcinoma Yes Yes Yes No
MR211_PDX1 EGFR lung progression disease Erlotinib Gefitinib EGFR deletion exon 19, EGFR:p.(Thr790Met) NSCLC adenocarcinoma Yes Yes Yes Yes
MR210_PDX1 ALK lung progression disease Lorlatinib Cisplatin; Crizotinib; Ceritinib ALK:p.(Cys1156Tyr) NSCLC adenocarcinoma Yes Yes Yes Yes
MR202_PDX1 EGFR lung progression disease Osimertinib Carboplatin-paclitaxel-bevacizumab ; Pemetrexed; Erlotinib EGFR:p.(Leu858Arg), EGFR:p.(Thr790Met), MDM2 amplification NSCLC adenocarcinoma Yes Yes Yes No
MR196_PDX1 EGFR lung progression disease Erlotinib EGFR deletion exon 19, EGFR:p.(Thr790Met), BRCA2 deletion, TP53:p.(Arg110Leu) NSCLC adenocarcinoma Yes Yes Yes Yes
MR191_PDX2 prostate prostate baseline Enzalutamide Docetaxel; Carboplatin BRCA2 (c.6373dup, p.Thr2125Asnfs*4), , XXX neuroendocrine Yes Yes Yes Yes
MR191_PDX1 prostate prostate baseline Enzalutamide Carboplatin BRCA2:p.(Val2118_Glu2123delinsLeuThrGlnLysTrpLys), BRCA2:p.(Thr2125Asnfs*4), XXX neuroendocrine Yes Yes Yes Yes
MR182_PDX1 prostate prostate baseline Enzalutamide AR ampllification, ATM:p.(Ile2998Argfs*9) (germline), XXX, XXX luminal phenotype Yes Yes Yes No
MR182_PDX2 prostate prostate progression disease Enzalutamide ATM:p.(Ile2998Argfs*9) (germline), XXX, XXX luminal phenotype Yes Yes Yes No
MR178_PDX1 prostate prostate progression disease Enzalutamide MSI , AR:p.(Leu702His), p.(His790Arg), p.(His875Tyr), NCOR1 truncating , NCOR2 truncating luminal phenotype Yes Yes Yes No
MR174_PDX1 FGFR cholangiocarcinoma progression disease Erdafitinib Gemcitabine-sunitinib-everolimus-FOLFIRI FGFR2:p.(Cys382Arg) , FGFR2:p.(Asn549Asp) Yes Yes Yes Yes
MR170_PDX1 prostate prostate progression disease Abiraterone Enzalutamide; Carboplatin XXX, TP53:p.(Phe134Val), RB1 deletion neuroendocrine phenotype Yes Yes Yes No
MR156_PDX1 EGFR lung progression disease Osimertinib Erlotinib; Gefitinib; Cisplatin; Pemetrexed EGFR deletion exon 19, EGFR:p.(Thr790Met), EGFR:p.(Cys797Ser), EGFR:p.(Ala750Pro) NSCLC adenocarcinoma Yes Yes Yes Yes
MR151_PDX1 prostate prostate progression disease Enzalutamide CDK12:p.(Leu866Trp), BRAF:p.(Lys601EGlu), XXX mixed phenotype Yes Yes Yes No
MR150_PDX1 prostate prostate progression disease Abiraterone Docetaxel; Cabazitaxel ; Carboplatin ATM:p.(Arg1466Pro), XXX, AKT1:p.(Glu17Lys) luminal phenotype Yes Yes Yes Yes
MR144_PDX1 ALK lung progression disease Brigatinib Crizotinib; Ceritinib EML4::ALK fusion, ALK:p.(Gly1202Arg) NSCLC adenocarcinoma Yes Yes Yes Yes
MR142_PDX1 other adenoid cystic carcinoma progression disease NOTCHi CDDP/navelbine NOTCH1 p.(Pro2465Argfs*11) Yes Yes Yes No
MR135_PDX1 ALK lung progression disease Lorlatinib Crizotinib EML4::ALK fusion, NF2 skip exon 10, TP53:p.(Arg273Pro) NSCLC adenocarcinoma Yes Yes Yes Yes
MR135_PDX2 ALK lung progression disease Lorlatinib Crizotinib EML4::ALK fusion, NF2 skip exon 10, NF2:p(.Lys543Asn), TP53:p.(Arg273Pro) NSCLC adenocarcinoma Yes Yes Yes Yes
MR131_PDX1 EGFR lung progression disease Osimertinib Gefitinib; Rociletinb EGFR:p.(Leu858Arg), EGFR:p.(Thr790Met), TP53:p.(Ser241Tyr), FGFR4:p.(Glu522Lys), PTEN:p.(Asp326His) NSCLC adenocarcinoma Yes Yes Yes Yes
MR123_PDX1 prostate prostate progression disease Enzalutamide Doxetaxel; Abiraterone; Cabazitaxel BRCA2 deletion luminal phenotype Yes Yes Yes Yes
MR122_PDX1 DDR colon progression disease AZD6736/Carboplatin FOLFOX; FOLFIRI ATM:p.(Gln2811Ter), NRAS:p.(Gln61Lys), APC:p.(Leu1342PhefsTer12) Yes Yes Yes Yes
MR104_PDX1 FGFR bladder progression disease Erdafitinib Cisplatin; Carboplatin; Gemcitabine FGFR3:p.(Ser249Cys), NF1 triple event, TP53:p.(Gly266Arg) Basal Squamous Yes Yes Yes No
MR103_PDX1 FGFR bladder progression disease Erdafitinib Carboplatin; Docetaxel FGFR2:p.(Asn549Asp), FGFR4:p.(Asp276Asn), TP53:p.(Cys275Tyr) papillary adenocarcinoma Yes Yes Yes Yes
MR097_PDX1 FGFR gynecological ovary progression disease Erdafitinib Carboplatin; Pazopanib FGFR2::FAM160B1 fusion, TACC2::FGFR2 fusion , TP53:p.(Pro278Ser) Yes Yes Yes Yes
MR097_PDX2 FGFR gynecological ovary stable disease Erdafitinib Carboplatin; Pazopanib FGFR2::FAM160B1 fusion, TACC2::FGFR2 fusion , TP53:p.(Pro278Ser) Yes Yes Yes Yes
MR090_PDX1 DDR gynecological endometrial stable disease ATR inhibitor AZD6738 Cisplatin; Paclitaxel; 5FU; Gemzitanib ERBB2:p.(Gly660Asp); p.(Ser310Tyr), PIK3CA:p.(Glu545Lys), BRCA2:p.(Gly1771Asp), ATM:p.(Ser2146Thr), ATRX:p.(Asp333Tyr) Yes Yes Yes Yes
MR086_PDX1 FGFR bladder progression disease Erdafitinib Cisplatin FGFR3:p.(Ser249Cys), PIK3CA:p.(Glu545Lys) Basal Squamous Yes Yes Yes Yes
MR086_PDX2 FGFR bladder stable disease Erdafitinib Cisplatin FGFR3:p.(Ser249Cys), FGFR3:p(.Asn540Lys) Basal Squamous Yes Yes Yes Yes
MR084_PDX1 prostate prostate baseline Enzalutamide Docetaxel PTEN deletion, RB1 deletion, TP53 deletion neuroendocrine phenotype Yes Yes Yes Yes
MR077_PDX1 prostate prostate baseline (primary resistance) ODM-204 Docetaxel; Enzalutamide; Abiraterone TP53:p.(Tyr220Cys), p.(Tyr88Cys),p.(Tyr181Cys),p.(Tyr61Cys), RB1 deletion, PTEN deletion mixed Yes Yes Yes Yes
MR059_PDX1 prostate prostate baseline Enzalutamide Docetaxel RB1 deletion, ATM deletion neuroendocrine phenotype Yes Yes Yes Yes
MR057_PDX1 ALK lung progression disease Lorlatinib Crizotinib EML4::ALK fusion, ALK:p.(Cys1156Tyr), ALK:p.(Gly1269Ala) NSCLC adenocarcinoma Yes Yes Yes Yes
MR041R_PDX1 ALK EML4::ALK fusion, ALK:p.(Gly1202Arg), ALK:p.(Gly134Arg) No Yes Yes No
MR041_PDX1 prostate prostate baseline Abiraterone PTEN deletion, TP53:p.(Gly245Ser), RET amplification, SF3B1:p.(Arg625Cys) luminal phenotype Yes Yes Yes Yes
MR015_PDX2 FGFR bladder stable disease Erdafitinib MVAC FGFR3:p.(Ser249Cys), ATM:p.(Leu2226Ter) Luminal Papillary Yes Yes Yes Yes
MR015_PDX1 FGFR bladder progression disease Erdafitinib MVAC FGFR3:p.(Ser249Cys), EGFR hyper phosphorylation, ATM:p.(Leu2226Ter) Luminal Papillary Yes Yes Yes Yes
MR014_PDX1 other lung progression disease Everolimus Pemetrexed-Cisplatin MTOR:p.(Pro465Thr), NOTCH2 réarrangement, CTNNB1:p.(Ser37phe) papillary adenocarcinoma Yes No Yes No
MR010_PDX1 other head and neck (parotid) progression disease LY3039478 (Notch1 inhibiteur) Pazopanib ; 5-FU-Cisplatin NOTCH1:p.(Ser2467*), MYB::NFIB fusion Yes Yes Yes Yes
MR009_PDX1 prostate prostate baseline Enzalutamide BRCA2:p.(Glu49*), TP53:p.(Tyr236DAsp) mixed phenotype Yes Yes Yes Yes
MR009_PDX2 prostate prostate progression disease Atezolizumab Enzalutamide BRCA2:p.(Glu49*), TP53:p.(Tyr236DAsp) mixed phenotype Yes Yes Yes No
MR009_PDX3 prostate prostate progression disease Olaparib Enzalutamide; Atezolizumab BRCA2:p.(Glu49*), BRCA2:p.(*49Glu), TP53:p.(Tyr236DAsp) neuroendocrine phenotype Yes Yes Yes No
MR007_PDX1 EGFR lung progression disease Osimertinib Gefitinib; Erlotinib; Carboplatin; Cetuximab EGFR:p.(Leu858Arg), MET amplification NSCLC adenocarcinoma Yes Yes Yes Yes
MR005_PDX1 KRAS gynecological endometrial progression disease inhibiteur de MEK et inhibiteur MDM2 Carboplatin; Paclitaxel KRAS:p.(Gly12Asp), XXX, XXX Yes Yes Yes Yes
M2057_PDX1 FGFR bladder progression disease Erdafitinib MVAC FGFR3:p.(Ser249Cys), PIK3R1 p.(Lys459del), PTEN p.(Cys136TyrfsTer10) Basal Squamous Yes Yes Yes Yes
ICARUS_BREAST01_PDX1 other breast progression disease Patritumab déruxtécan Tamoxifene-taxol; Letrozole-palbociclib; Letrozole; Capecitabine NOTCH3 p.(Cys875Tyr), KMT2C p.(Arg4524GlyfsTer102) HER2 + Yes Yes Yes No
DSRCT-03_PDX1 DSRCT sarcoma EWS::WT1 fusion No No Yes No
D02-037_PDX1 HER2 breast progression disease Trastuzumab-deruxtecan Docetaxel-herceptine; Taxol-herceptine-perjeta-xgeva; Eribulin-herceptine EGFR amplification, PTEN:p.(Phe21leu) HER2 + Yes Yes Yes Yes
Bellini_PDX1 BRAF bellini baseline CDDP-gemzar-avastin BRAF:p.(Gly466Ala) Yes Yes Yes No
MR087_PDX2 BRAF bellini progression disease Trametinib CDDP-gemzar-avastin BRAF:p.(Gly466Ala), MET amplification, JAK3:p.(Val722Ile) Yes Yes Yes No
MR087_PDX3 BRAF bellini progression disease Trametinib CDDP-gemzar-avastin BRAF amplification Yes Yes Yes No